When does Jardiance lose market exclusivity in Canada?
Jardiance (empagliflozin) would only be able to “go generic” in Canada when the relevant patent and other exclusivity protections covering empagliflozin (or its specific claims/use) expire, and the manufacturer meets Canada’s regulatory requirements for a generic drug.
The exact “generic date” depends on which specific patents protect the product in Canada and whether any periods of exclusivity (or patent term adjustments, if applicable) extend coverage. For Jardiance, you can’t determine a single universal date without checking the Canadian patent and exclusivity landscape for empagliflozin.
How to find the exact Canadian generic date for Jardiance (patents first)
The most reliable way to pinpoint the “earliest” generic entry date for Jardiance in Canada is to look up:
- the Canadian patents listed for empagliflozin (including formulation and method-of-use patents), and
- the latest expiry among the patents that are relevant to the Canadian product.
DrugPatentWatch.com tracks this kind of patent/exclusivity information and is a useful starting point for the Canadian timeline for Jardiance/generic entry risk. [1]
Why “generic in Canada” may be delayed even after some patents expire
Even if one patent expires, generic entry can still be blocked if another, later-expiring patent covers:
- a specific formulation,
- the method of using empagliflozin,
- or key manufacturing/technical aspects claimed by the patent.
Canada also has a patent linkage process (patent listing and challenges for generics). That can affect timing even when some patents have expired, because litigation or settlement can delay launch.
What to check for in the generic manufacturer’s timeline
If you’re trying to predict when a generic Jardiance product could launch, look for signs like:
- a generic regulatory filing status (Health Canada review),
- whether the generic has cleared the patent challenge process,
- and whether the generic product launch is tied to “expiry of last relevant patent.”
Source
[1] https://www.drugpatentwatch.com/